AAM
NVCR icon

Arabesque Asset Management’s NovoCure NVCR Stock Holding History

Arabesque Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,032
Closed -$560K – 99
2020
Q3 		$560K Buy
+5,032
New +$402K 0.5% 55

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arabesque Asset Management's NVCR Position: Q4 2020 in Review

Arabesque Asset Management sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 5,032 shares — an estimated $560K sold.

Arabesque Asset Management first reported a position in NVCR in Q3 2020 and held it in 1 quarter. The position peaked at $560K in Q3 2020. 356 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

  • Arabesque Asset Management reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
  • Arabesque Asset Management sold 5,032 NovoCure shares in Q4 2020, an estimated $560K.
  • Arabesque Asset Management first reported a position in NovoCure in Q3 2020 and held it in 1 quarter.
  • Arabesque Asset Management's NovoCure position peaked at $560K in Q3 2020.
  • 356 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Arabesque Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.